Galiwango, Ronald M. http://orcid.org/0000-0003-3702-5722
Bagaya, Bernard
Mpendo, Juliet
Joag, Vineet
Okech, Brenda
Nanvubya, Annet
Ssetaala, Ali
Muwanga, Moses
Kaul, Rupert
Funding for this research was provided by:
Institute of Infection and Immunity (TMI-138656)
Fogarty International Center (4D43TW009578-04)
Ontario HIV Treatment Network (Endowed Chair in HIV Research)
Article History
Received: 26 December 2018
Accepted: 29 June 2019
First Online: 19 July 2019
Ethics approval and consent to participate
: The study has been approved by the UVRI-REC (ref. no. GC/127/17/07/613), the Uganda National Council for Science and Technology (ref. no. HS 2299), and the Uganda NDA (CTA0041). All study participants will consent to participate in the study on the basis of appropriate information and with adequate time to consider this information and ask questions, if any, to the study team clinical staff. Participant consent to participate must be indicated by signing or marking (initials and/or thumbprint) and by dating the Informed Consent Document (ICD), witnessed by a member of the study team. A summary of any drug adverse effects experienced by study participants will be submitted to both the UVRI-REC and the Uganda NDA at study completion. Any serious adverse events will be immediately reported to the UVRI-REC and NDA, and affected participants will be treated at no cost.
: Consent for publication is not applicable as only anonymized data will be published.
: The authors declare that they have no competing interests.